197 related articles for article (PubMed ID: 32990511)
21. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
Alfano G; Fontana F; Ferrari A; Solazzo A; Perrone R; Giaroni F; Torricelli P; Cappelli G
Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
[TBL] [Abstract][Full Text] [Related]
22. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
23. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
[TBL] [Abstract][Full Text] [Related]
24. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
Piersson AD; Gorleku PN
Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
[TBL] [Abstract][Full Text] [Related]
25. The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents.
Lee Y; Kim J; Kwon S; Jeong JC; Joo KW; Oh KH
Acta Radiol; 2023 Aug; 64(8):2492-2496. PubMed ID: 37128169
[TBL] [Abstract][Full Text] [Related]
26. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.
Lauenstein T; Ramirez-Garrido F; Kim YH; Rha SE; Ricke J; Phongkitkarun S; Boettcher J; Gupta RT; Korpraphong P; Tanomkiat W; Furtner J; Liu PS; Henry M; Endrikat J
Invest Radiol; 2015 Jun; 50(6):416-22. PubMed ID: 25756684
[TBL] [Abstract][Full Text] [Related]
27. Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging.
Shimoji K; Aoki S; Nakanishi A; Suzuki M; Hori M; Sato S; Hoshito H; Kyogoku S; Cho N; Ozaki Y; Suzuki M; Kuwatsuru R; Sasai K
Jpn J Radiol; 2012 Feb; 30(2):116-9. PubMed ID: 22200915
[TBL] [Abstract][Full Text] [Related]
28. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
[TBL] [Abstract][Full Text] [Related]
29. Nephrogenic systemic fibrosis: history and epidemiology.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
[TBL] [Abstract][Full Text] [Related]
30. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
31. Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.
Kanal E; Patton TJ; Krefting I; Wang C
AJNR Am J Neuroradiol; 2020 Mar; 41(3):393-399. PubMed ID: 32115422
[TBL] [Abstract][Full Text] [Related]
32. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
[TBL] [Abstract][Full Text] [Related]
33. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
34. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
35. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
36. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function.
Bridges MD; St Amant BS; McNeil RB; Cernigliaro JG; Dwyer JP; Fitzpatrick PM
AJR Am J Roentgenol; 2009 Jun; 192(6):1538-43. PubMed ID: 19457816
[TBL] [Abstract][Full Text] [Related]
37. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis:
Alabousi M; Davenport MS
Radiology; 2021 Aug; 300(2):279-284. PubMed ID: 34060939
[TBL] [Abstract][Full Text] [Related]
38. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
39. The use of gadolinium for arterial interventions.
Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
[TBL] [Abstract][Full Text] [Related]
40. [Nephrogenic systemic fibrosis and use of MR contrast media].
Christiansen RE; Sviland L; Sekse I; Svarstad E
Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
